Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer

Background: Oncotype Dx is used to predict the long-term recurrence risk in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer (BC). This study aimed at establishing a correlation between clinicopathological parameters an...

Full description

Bibliographic Details
Main Authors: Abdulmohsen Alkushi, Ahmad Omair, Haitham Arabi, Emad Masuadi, Omalkhair Abualkhair
Format: Article
Language:English
Published: SAGE Publishing 2020-12-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.1177/1178223420977848
id doaj-aa2c42df5fa84eacb824fd76fda8eeb6
record_format Article
spelling doaj-aa2c42df5fa84eacb824fd76fda8eeb62020-12-09T00:04:31ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342020-12-011410.1177/1178223420977848Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast CancerAbdulmohsen Alkushi0Ahmad Omair1Haitham Arabi2Emad Masuadi3Omalkhair Abualkhair4College of Medicine, King Saud bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center Riyadh, Saudi ArabiaCollege of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center, Riyadh, Saudi ArabiaDepartment of Pathology, King Abdulaziz Medical City of National Guard, Riyadh, Saudi ArabiaCollege of Medicine, King Saud bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center Riyadh, Saudi ArabiaDepartment of Oncology, Specialized Medical Center, Riyadh, Saudi ArabiaBackground: Oncotype Dx is used to predict the long-term recurrence risk in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer (BC). This study aimed at establishing a correlation between clinicopathological parameters and recurrence score (RS), subsequently improving predictability and ultimately justifying the use of the multigene assay. Materials and methods: A retrospective analysis of the pathology and clinical data of 114 female patients with BC who had Oncotype Dx testing between 2012 and 2019. The pathological parameters included are tumor cell type, tumor grade, pathological stage, and mitotic index (MI). The expression of ER, progesterone receptor (PR), HER2, and Ki67 was assessed by immunohistochemistry. A univariate and multivariate linear regression analysis was performed to assess the correlation between these parameters and the RS. Results: In univariate analysis, age (˂40 years), higher tumor grade, and low PR expression were significantly associated with higher RS ( P  = .02; ˂.001; and ˂.001, respectively). Both MI and Ki67 were also strongly correlated with an increase in the RS with a P value of .01 (Spearman correlation 0.34 and 0.33). In multivariate linear regression analysis, age, MI, and Ki67 lost their significance, but both higher grade and PR remained significantly associated with a higher RS along with the tumor stage ( P  ˂ .001; ˂.001; and .04, respectively). Conclusions: Tumor grade and PR immunohistochemical expression are the main predictors of RS in our study population. Other clinicopathological features were not significant predictors of change in RS in multivariate analysis.https://doi.org/10.1177/1178223420977848
collection DOAJ
language English
format Article
sources DOAJ
author Abdulmohsen Alkushi
Ahmad Omair
Haitham Arabi
Emad Masuadi
Omalkhair Abualkhair
spellingShingle Abdulmohsen Alkushi
Ahmad Omair
Haitham Arabi
Emad Masuadi
Omalkhair Abualkhair
Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
Breast Cancer: Basic and Clinical Research
author_facet Abdulmohsen Alkushi
Ahmad Omair
Haitham Arabi
Emad Masuadi
Omalkhair Abualkhair
author_sort Abdulmohsen Alkushi
title Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
title_short Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
title_full Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
title_fullStr Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
title_full_unstemmed Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
title_sort predictability of 21-gene recurrence score assay by using pathological and immunohistochemical parameters in breast cancer
publisher SAGE Publishing
series Breast Cancer: Basic and Clinical Research
issn 1178-2234
publishDate 2020-12-01
description Background: Oncotype Dx is used to predict the long-term recurrence risk in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer (BC). This study aimed at establishing a correlation between clinicopathological parameters and recurrence score (RS), subsequently improving predictability and ultimately justifying the use of the multigene assay. Materials and methods: A retrospective analysis of the pathology and clinical data of 114 female patients with BC who had Oncotype Dx testing between 2012 and 2019. The pathological parameters included are tumor cell type, tumor grade, pathological stage, and mitotic index (MI). The expression of ER, progesterone receptor (PR), HER2, and Ki67 was assessed by immunohistochemistry. A univariate and multivariate linear regression analysis was performed to assess the correlation between these parameters and the RS. Results: In univariate analysis, age (˂40 years), higher tumor grade, and low PR expression were significantly associated with higher RS ( P  = .02; ˂.001; and ˂.001, respectively). Both MI and Ki67 were also strongly correlated with an increase in the RS with a P value of .01 (Spearman correlation 0.34 and 0.33). In multivariate linear regression analysis, age, MI, and Ki67 lost their significance, but both higher grade and PR remained significantly associated with a higher RS along with the tumor stage ( P  ˂ .001; ˂.001; and .04, respectively). Conclusions: Tumor grade and PR immunohistochemical expression are the main predictors of RS in our study population. Other clinicopathological features were not significant predictors of change in RS in multivariate analysis.
url https://doi.org/10.1177/1178223420977848
work_keys_str_mv AT abdulmohsenalkushi predictabilityof21generecurrencescoreassaybyusingpathologicalandimmunohistochemicalparametersinbreastcancer
AT ahmadomair predictabilityof21generecurrencescoreassaybyusingpathologicalandimmunohistochemicalparametersinbreastcancer
AT haithamarabi predictabilityof21generecurrencescoreassaybyusingpathologicalandimmunohistochemicalparametersinbreastcancer
AT emadmasuadi predictabilityof21generecurrencescoreassaybyusingpathologicalandimmunohistochemicalparametersinbreastcancer
AT omalkhairabualkhair predictabilityof21generecurrencescoreassaybyusingpathologicalandimmunohistochemicalparametersinbreastcancer
_version_ 1724388665715589120